NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Reapplix

Reapplix

Private
DenmarkHealthcare & Life Scienceshttps://reapplix.com/

Last Round

Series B

Jul 14, 2020

Total Funding Raised

$22.6M

Company Overview

Reapplix is a regenerative medicine company that develops and manufactures the 3C Patch System, an innovative biological wound therapy for the treatment of hard-to-heal diabetic foot ulcers.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

wound careregenerative medicineautologous therapypoint-of-carewound healingchronic wound treatmentmedical devicePRFplatelet-rich fibrinmedtechbiologicsbiotechdiabetic foot ulcerbiomaterials

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Reapplix Comparables

Compare Reapplix with similar companies based on industry and business-model similarity.

Reapplix comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
RedDress
90%
Velora Wound Care
85%
Nuo Therapeutics Inc
82%

Reapplix Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJul 14, 2020
VC RoundSep 27, 2016

Key People

Founding team and executive leadership

Kira Rupprecht

Chief Executive Officer and Board Member

Executive Team

Morten Have-Rasmussen

CFO

Executive Team

Carsten Heinze

Chief Operating Officer

Executive Team

Reapplix Investors

Notable investors and investment history

Reapplix investors
InvestorRounds
Lauxera Capital PartnersSeries B
Novo HoldingsSeries B
SEED CapitalVC Round
North-East Health Care Investment ApSSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 14, 2020

    $23M round with participation from Novo Holdings and Lauxera Capital Partners.

  • Sep 27, 2016

    $3M round led by Novo Holdings and SEED Capital.

Reapplix Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Reapplix Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Reapplix's valuation, stock price, and market status.

Firmographic Details

HeadquartersDenmark
Employee Range42
Year Founded2008
Last FundingJul 14, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.